Gain Therapeutics Stock Book Value Per Share

GANX Stock

USD 1.72 0.10 6.17%

Gain Therapeutics fundamentals help investors to digest information that contributes to Gain Therapeutics' financial success or failures. It also enables traders to predict the movement of Gain Stock. The fundamental analysis module provides a way to measure Gain Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gain Therapeutics stock.

	Last Reported	Projected for Next Year
Book Value Per Share	0.97	0.84
Tangible Book Value Per Share	0.95	0.83

Book Value Per Share is likely to drop to 0.84 in 2024. Tangible Book Value Per Share is likely to drop to 0.83 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gain Therapeutics Company Book Value Per Share Analysis

Gain Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current Gain Therapeutics Book Value Per Share

0.78 X

Most of Gain Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gain Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Gain Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Gain Therapeutics is extremely important. It helps to project a fair market value of Gain Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Gain Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gain Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gain Therapeutics' interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Long Term Debt	Short Long Term Debt	Intangible Assets	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.72	0.71	0.67	0.99	0.91	0.48	0.98	0.97	0.22	-0.92	0.87	0.97	0.89	0.97	0.99	-0.77	0.91	-0.16	-0.34	-0.34
Retained Earnings	-0.72		-0.82	-0.97	-0.67	-0.9	0.2	-0.71	-0.65	-0.71	0.49	-0.91	-0.66	-0.91	-0.65	-0.74	0.99	-0.92	0.58	0.81	0.81
Accounts Payable	0.71	-0.82		0.7	0.68	0.85	-0.1	0.71	0.65	0.26	-0.42	0.94	0.66	0.9	0.63	0.67	-0.83	0.82	-0.15	-0.43	-0.43
Net Receivables	0.67	-0.97	0.7		0.63	0.83	-0.14	0.66	0.61	0.83	-0.52	0.84	0.62	0.86	0.61	0.7	-0.93	0.85	-0.73	-0.9	-0.9
Total Current Assets	0.99	-0.67	0.68	0.63		0.86	0.53	1.0	1.0	0.16	-0.94	0.83	1.0	0.85	0.99	0.99	-0.73	0.88	-0.17	-0.32	-0.32
Common Stock	0.91	-0.9	0.85	0.83	0.86		0.11	0.87	0.83	0.44	-0.71	0.96	0.83	0.97	0.82	0.9	-0.92	0.98	-0.25	-0.51	-0.51
Property Plant Equipment	0.48	0.2	-0.1	-0.14	0.53	0.11		0.48	0.53	-0.34	-0.73	0.07	0.53	0.13	0.56	0.45	0.16	0.08	0.2	0.31	0.31
Total Assets	0.98	-0.71	0.71	0.66	1.0	0.87	0.48		1.0	0.19	-0.92	0.85	1.0	0.87	0.99	0.99	-0.77	0.9	-0.22	-0.38	-0.38
Total Stockholder Equity	0.97	-0.65	0.65	0.61	1.0	0.83	0.53	1.0		0.14	-0.94	0.8	1.0	0.82	1.0	0.98	-0.72	0.86	-0.2	-0.33	-0.33
Current Deferred Revenue	0.22	-0.71	0.26	0.83	0.16	0.44	-0.34	0.19	0.14		-0.16	0.43	0.15	0.48	0.16	0.28	-0.62	0.45	-0.86	-0.91	-0.91
Net Debt	-0.92	0.49	-0.42	-0.52	-0.94	-0.71	-0.73	-0.92	-0.94	-0.16		-0.65	-0.94	-0.7	-0.96	-0.93	0.54	-0.72	0.21	0.26	0.26
Total Liab	0.87	-0.91	0.94	0.84	0.83	0.96	0.07	0.85	0.8	0.43	-0.65		0.81	0.99	0.8	0.85	-0.92	0.94	-0.3	-0.56	-0.56
Net Invested Capital	0.97	-0.66	0.66	0.62	1.0	0.83	0.53	1.0	1.0	0.15	-0.94	0.81		0.83	1.0	0.98	-0.73	0.87	-0.2	-0.34	-0.34
Capital Stock	0.89	-0.91	0.9	0.86	0.85	0.97	0.13	0.87	0.82	0.48	-0.7	0.99	0.83		0.82	0.87	-0.91	0.94	-0.34	-0.58	-0.58
Net Working Capital	0.97	-0.65	0.63	0.61	0.99	0.82	0.56	0.99	1.0	0.16	-0.96	0.8	1.0	0.82		0.98	-0.71	0.85	-0.21	-0.34	-0.34
Short Term Debt	0.99	-0.74	0.67	0.7	0.99	0.9	0.45	0.99	0.98	0.28	-0.93	0.85	0.98	0.87	0.98		-0.8	0.92	-0.26	-0.42	-0.42
Long Term Debt	-0.77	0.99	-0.83	-0.93	-0.73	-0.92	0.16	-0.77	-0.72	-0.62	0.54	-0.92	-0.73	-0.91	-0.71	-0.8		-0.96	0.51	0.75	0.75
Short Long Term Debt	0.91	-0.92	0.82	0.85	0.88	0.98	0.08	0.9	0.86	0.45	-0.72	0.94	0.87	0.94	0.85	0.92	-0.96		-0.34	-0.58	-0.58
Intangible Assets	-0.16	0.58	-0.15	-0.73	-0.17	-0.25	0.2	-0.22	-0.2	-0.86	0.21	-0.3	-0.2	-0.34	-0.21	-0.26	0.51	-0.34		0.94	0.94
Long Term Debt Total	-0.34	0.81	-0.43	-0.9	-0.32	-0.51	0.31	-0.38	-0.33	-0.91	0.26	-0.56	-0.34	-0.58	-0.34	-0.42	0.75	-0.58	0.94		1.0
Capital Surpluse	-0.34	0.81	-0.43	-0.9	-0.32	-0.51	0.31	-0.38	-0.33	-0.91	0.26	-0.56	-0.34	-0.58	-0.34	-0.42	0.75	-0.58	0.94	1.0

Click cells to compare fundamentals

The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Competition

Predict Gain Therapeutics

Book Value Per Share Over Time

Gain Common Stock Shares Outstanding

Common Stock Shares Outstanding

11.86 Million

At this time, Gain Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year.

In accordance with the recently published financial statements, the book value per share of Gain Therapeutics is about 0.776 times. This is 145.65% lower than that of the Biotechnology sector and 100.31% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.96% higher than that of the company.

Gain Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gain Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gain Therapeutics could also be used in its relative valuation, which is a method of valuing Gain Therapeutics by comparing valuation metrics of similar companies.

Gain Therapeutics is currently under evaluation in book value per share category among its peers.

Gain Fundamentals

	Return On Equity	-1.89
	Return On Asset	-0.73
	Current Valuation	34.34 M
	Shares Outstanding	26.53 M
	Shares Owned By Insiders	5.09 %
	Shares Owned By Institutions	7.96 %
	Number Of Shares Shorted	658.34 K
	Price To Book	5.12 X
	Price To Sales	925.92 X
	Revenue	55.18 K
	Gross Profit	(7.66 M)
	EBITDA	(22.17 M)
	Net Income	(22.27 M)
	Cash And Equivalents	24.25 M
	Cash Per Share	2.04 X
	Total Debt	1.03 M
	Debt To Equity	0.05 %
	Current Ratio	7.58 X
	Book Value Per Share	0.78 X
	Cash Flow From Operations	(18.87 M)
	Short Ratio	1.65 X
	Earnings Per Share	(1.07) X
	Target Price	7.4
	Number Of Employees	29
	Beta	0.34
	Market Capitalization	45.62 M
	Total Asset	18.61 M
	Retained Earnings	(60.78 M)
	Working Capital	12.83 M
	Net Asset	18.61 M

About Gain Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Gain Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC